ClinicalTrials.gg
TerminatedNCT05785390BOSS-002Updated Aug 13, 2026Results posted

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

A Phase 2 interventional study of NP-101 and Placebo in COVID-19, sponsored by Novatek Pharmaceuticals. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Novatek Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
The interim analysis results met protocol and SAP predetermined criteria for stopping early due to futility or efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
518th of 1,321
170 · median 91
Started
2023
with 130 others
Phase 2
349 of 1,859
14 open now
Registered
1,620th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 518th largest by enrollment of the 1,321 interventional ones that give a count, is one of 131 that started in 2023, is one of 349 in phase 2, and was the 1,620th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of NP-101 in treating high-risk participants who have tested positive for Covid-19. The main question[s] it aims to answer are:

  • To evaluate the safety of NP-101, as well as establish the maximum tolerated dose in high risk Covid-19 positive patients.

Participants will [describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items]. If there is a comparison group: Researchers will compare [insert groups] to see if [insert effects].

Read the detailed description

This is a Phase IIa/IIb multicenter, interventional, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of NP-101 in outpatient high-risk COVID-19 positive participants. Blinding roles: Participants, Investigators and Sponsor

The study is comprised of two parts (Phase IIa and Phase IIb) and four cohorts. The first part of the trial (IIa) involves three cohorts and is a dose escalation study designed to select the maximum tolerated dose for use in the second part (IIb) of the study. In the dose escalation (Phase IIa) portion of the trial (n= 60), qualified participants will be enrolled in a parallel dose escalation design and randomized in a 3:1 [active+best supportive care (BSC):placebo+BSC]ratio to one of three cohorts of 20 participants each (15 active +BSC, 5 placebo + BSC). Cohort 1 (15 participants taking 600 mg capsules for a total daily dose of 3 grams of NP-101 plus BSC and 5 participants taking placebo plus BSC), and Cohort 2 (15 participants taking 600 mg capsules for a total daily dose of 4.8 g of NP-101+ BSC and 5 participants taking placebo plus BSC will run concurrently since acceptable safety data for the 3 g dose was obtained in an earlier phase II study.

Cohort 1 will receive either 3 g Total Daily Dose (TDD) of NP-101 + BSC or Placebo+ BSC, Cohort 2 will receive either 4.8 g TDD of NP-101 +BSC or placebo + BSC) and Cohort 3 (15 participants taking 600 mg capsules for a total daily dose of 6 g of NP-101 + BSC and 5 participants taking placebo plus BSC.) Safety will be evaluated according to the terms of the Statistical Analysis Plan (SAP). In the second portion of the trial (Phase IIb), Participants enrolled in Cohort 4 (n= 248) will be randomized in a ratio of 1:1 (active+BSC : placebo+BSC) and will receive the Maximum Tolerated Daily Dose (MTDD) as determined by the parameters set by the SAP and approved by the pharmacovigilance team.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID-19
  • High Risk
  • Outpatient
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • A resting SpO2 of >93% on room air.
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18 and over, presenting with mild to moderate clinical symptoms of Covid- 19 infection (per FDA guidance - see appendix 3) with symptom onset within 5 days prior to the day of randomization
  • Positive COVID-19 infection confirmed by RT-PCR within the last 5 days of the day of randomization
  • A score of ≥ 2 (moderate) on a minimum of 1 symptom on the PRO Symptom Survey on the day of randomization
  • Ability to take oral medication and be willing to adhere to the dosing regimen (Twice a day - BID for 14 days)
  • For females of : negative pregnancy test at screening and use of highly effective method during study participation and for an additional 4 weeks after the end of study drug administration
  • For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of study drug administration
  • Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration
  • To be considered high risk, participants should have at least one of the following conditions:

    • age ≥60 years;
    • active cancer
    • chronic kidney disease;
    • chronic lung disease including
    • Obesity ( ≥30)
    • serious heart conditions [heart failure, coronary artery disease, or cardiomyopathies];
    • Diabetes (type 1 or type 2)
    • state (weakened immune system or diseases)
    • Chronic liver disease
    • Cystic fibrosis
    • infection
    • Smoking, current or former
    • Sickle cell disease or thalassemia
    • Solid organ or blood stem cell transplant
    • Stroke or cerebrovascular disease

Exclusion criteria

Exclusion Criteria:

  • Current or recent (within 4 weeks) treatment with any ; however, inhaled steroids, which are used to treat acute or chronic bronchial inflammation, will be permitted
  • Severe Covid-19 symptoms (severe per FDA classification - see appendix 3)
  • Requires immediate admission to hospital for any reason
  • Pregnancy or lactation
  • Known allergic reactions to components of black seed oil or thymoquinone
  • Treatment with another drug or other investigational intervention within 2 weeks of study start and throughout study duration.
  • Significant hepatic disease (/AST> 4 times the ); any laboratory parameter >/= 4 times the ULN or count \<100,000/µ L or neutrophilic granulocyte absolute count

    o \<500/mm3

  • History of moderate to severe CKD, (i.e. on hemodialysis or has an estimated less than 45mL/min) at the time of enrollment
  • Participants with inflammatory bowel disease (such as Crohn's) that could affect the intestinal absorption of NP-101 enteric coated capsules.
  • Known uncontrolled (with a recent viral load > 50 copies/mL or CD4\<200 cells/mm3 or known active uncontrolled (defined as HBsAg-positive or detectable HBV DNA viral load) or known active (defined as detectable HCV RNA viral load) infection
  • Influenza diagnosis (confirmed by testing) during screening or within prior 14 days
  • Any uncontrolled condition(s) or diagnosis, both physical or psychological, or physical exam finding that precludes participation, as per investigator
  • Current treatment with CYP2C9 substrates (see Appendix 5)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Active Drug Treatment

    Phase IIa - Dose escalation. 3g cohort and 4.8g cohort run simultaneously, followed by a 6 g cohort. Administered in 600 g capsules of NP-101 for a total daily dose of 3g, 4.8g and 6g adminstered BID. Administered for 14 days.Establish MTDD Phase IIB - Continue study with MTDD as established above.

    Drug: NP-101

  • Placebo comparator
    Placebo

    As above, except dosed with matching placebo capsules.

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Establishment of MTDD

    Number of DLTS (Dose Limiting Toxicities) in the NP-101 arm at each dose compared to placebo and the safety threshold. This outcome measure ONLY APPLIES TO the Phase-IIa (Dose-finding) component of the trial.

    Time frame: Fourteen days per dose (Phase IIA Only)

  2. Safety and Tolerability of NP-101 vs Placebo (Phase IIa and IIb)

    Evaluation of the number of overall adverse events, related adverse reactions, adverse events leading to discontinuation of study drug, hospitalization, or death.

    Time frame: Through Day 45

  3. Time to Sustained Clinical Recovery

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. This outcome measure is defined as the difference of Sustained Clinical Recovery (SCR) rates on Day 5 in patients taking the MTDD of NP-101 vs Placebo.

    Time frame: Through Day 5

Secondary outcomes

  1. Difference of Change in Log2 of Viral Load From Baseline to Day-7 Between NP-101 and Placebo

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.

    Time frame: Enrollment to Day-7 on study

  2. Difference of Change in ORF1 Gene From Baseline to Day-7 Between NP-101 and Placebo

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7

    Time frame: Enrollment to Day-7

  3. Difference in Change of E-Gene From Baseline to Day-7 Between N101 and Placebo

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.

    Time frame: From Enrollment to Day-7

  4. Differenc in Change of N-Gene From Baseline to Day-7 Between NP-101 and Placebo

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. . With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.

    Time frame: From enrollment to Day-7

  5. RT-PCR Negative/Undetectable Rate at Day 7

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the percentage of RT-PCR negative/undetectable (i.e., viral clearance) on Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo

    Time frame: Days 0 to 7

  6. RT-PCR Negative/Undetectable on Day-14

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the percentage of RT-PCR negative/undetectable (i.e., viral clearance) on Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo

    Time frame: Day 0 to Day-14

  7. Median Time to Sustained Clinical Recovery

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of Sustained Clinical Recovery between NP-101 and Placebo arms

    Time frame: From Day-0 to Day-28

  8. Median Day to Complete Clinical Recovery

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of Sustained Clinical Recovery between NP-101 and Placebo arms

    Time frame: From Day-0 to Day-28

  9. Median Days to Complete Clinical Resolution

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of the complete clinical resolution between NP-101 and Placebo.

    Time frame: From Day-0 to Day-28

  10. Difference of the Change From Randomization to Day-7 of Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+ Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. Markers are absolute counts of cells per cubic milimeter.

    Time frame: From Day-0 to Day-7

  11. Difference of the Change From Randomization to Day-7 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in the ratio of CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. Both CD4+ and CD8+ are measured as absolute counts of cells per cubic milimeter.

    Time frame: From Day-0 to Day-7

  12. Difference of the Change From Randomization to Day-7 of Percentages of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+ Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. These marker entries represent the percentages of the combination of these immune cell types or their percentages in the biological sample.

    Time frame: From Day-0 to Day-7 Cell Percentages

  13. Difference of the Change From Randomization to Day-14 of Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+. Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. Markers are absolute count of cells per cubic milimeter.

    Time frame: From Day*0 to Day-14

  14. Difference of the Change From Randomization to Day-14 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in the ratio of CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. Both CD4+ and CD8+ are measured as absolute counts of cells per cubic milimeter.

    Time frame: From Day-0 to Day-14

  15. Difference of the Change From Randomization to Day-14 of Percentages of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+. Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. These Markers represent the percentages of the combination of these immune cell types or their percentages in the biological sample.

    Time frame: From Day-0 to Day-14

  16. Proportion of Participants With Symptom Progression

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the rate of disease progression measured by the worsening by the Covid-19 symptoms from 'none' or 'mild' to 'moderate' or 'severe' and remaining at that level for at least two days before alleviation or resolution, or the experience of hospitalization or death due to Covid-19 symptom worsening in participants taking the MED of NP-101 versus placebo

    Time frame: From Day-0 to Day28

  17. Proportion of Paticipants With Long-Covid Symptoms

    This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the rate of Long- Covid symptoms in participants taking the MED of NP-101 versus placebo. A patient will be classified as having experienced symptoms indicative of Long- Covid if they reported any new or ongoing mild, moderate, or severe Long- Covid symptoms captured on the daily symptom questionnaire, on any of the following days: Day 30 ± 2 days, Day 37 ± 2 days, or Day 45 ± 2 days

    Time frame: Day-29 to Day-45

07

Results

Posted Aug 13, 2026

Participant flow

60 participants were enrolled during the Phase-IIa component of the trial during which we identified the Phase-IIb dose. The remaining 110 participants were enrolled on the study during the Phase-IIb component.

Participant flow — Overall Study
MilestonePhase-IIa NP-101, Dose 3gPhase-IIa Placebo, Dose 3gPhase-IIa NP-101, Dose 4.8gPhase-IIa Placebo, Dose 4.8gPhase-IIa NP-101, Dose 6gPhase-IIa Placebo, Dose 6gPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Started1551551555060
Completed1551551555060
Not completed00000000

Outcome measures

PrimaryEstablishment of MTDD

Number of DLTS (Dose Limiting Toxicities) in the NP-101 arm at each dose compared to placebo and the safety threshold. This outcome measure ONLY APPLIES TO the Phase-IIa (Dose-finding) component of the trial.

Time frame:
Fourteen days per dose (Phase IIA Only)
Reported as:
Count of participants · Participants
Establishment of MTDD
ParticipantsPhase-IIa NP-101, Dose 3gPhase-IIa NP-101, Dose 4.8gPhase-IIa NP-101, Dose 6g
Establishment of MTDD000
PrimarySafety and Tolerability of NP-101 vs Placebo (Phase IIa and IIb)

Evaluation of the number of overall adverse events, related adverse reactions, adverse events leading to discontinuation of study drug, hospitalization, or death.

Time frame:
Through Day 45
Reported as:
Count of participants · Participants
Safety and Tolerability of NP-101 vs Placebo (Phase IIa and IIb)
ParticipantsPhase-IIa NP-101, Dose 3gPhase-IIa Placebo, Dose 3gPhase-IIa NP-101, Dose 4.8Phase-IIa Placebo, Dose 4.8gPhase-IIa NP-101, Dose 6gPhase-IIa Placebo, Dose 6gPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Number of Participants with Adverse Events (AE) attributable to the study madication114272812
Number of Participants with Adverse Events (AE) regardless of attribution43631241932
Number of Patients with serious adverse events (SAE) attributable to the study medication00000000
No. of Patients with serious adverse events (SAE) regardless of attributable to the study medication00000000
Number of Patients with adverse events (AE) leading to d/c of study drug, hospitalization or death.00000000
PrimaryTime to Sustained Clinical Recovery

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. This outcome measure is defined as the difference of Sustained Clinical Recovery (SCR) rates on Day 5 in patients taking the MTDD of NP-101 vs Placebo.

Time frame:
Through Day 5
Reported as:
Count of participants · Participants
Time to Sustained Clinical Recovery
ParticipantsPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Time to Sustained Clinical Recovery2836
SecondaryDifference of Change in Log2 of Viral Load From Baseline to Day-7 Between NP-101 and Placebo

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.

Time frame:
Enrollment to Day-7 on study
Reported as:
Mean · Log-2 of the number of copies/mL
Difference of Change in Log2 of Viral Load From Baseline to Day-7 Between NP-101 and Placebo
Log-2 of the number of copies/mLPhase-IIb nP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Difference of Change in Log2 of Viral Load From Baseline to Day-7 Between NP-101 and Placebo5.11 ± 7.099.63 ± 4.43
SecondaryDifference of Change in ORF1 Gene From Baseline to Day-7 Between NP-101 and Placebo

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7

Time frame:
Enrollment to Day-7
Reported as:
Mean · No of amplification cycles for detection
Difference of Change in ORF1 Gene From Baseline to Day-7 Between NP-101 and Placebo
No of amplification cycles for detectionPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Difference of Change in ORF1 Gene From Baseline to Day-7 Between NP-101 and Placebo5.35 ± 7.3410.08 ± 4.64
SecondaryDifference in Change of E-Gene From Baseline to Day-7 Between N101 and Placebo

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.

Time frame:
From Enrollment to Day-7
Reported as:
Mean · No of amplification cycles for detection
Difference in Change of E-Gene From Baseline to Day-7 Between N101 and Placebo
No of amplification cycles for detectionPhase IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Difference in Change of E-Gene From Baseline to Day-7 Between N101 and Placebo4.92 ± 7.7610.14 ± 5.01
SecondaryDifferenc in Change of N-Gene From Baseline to Day-7 Between NP-101 and Placebo

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. . With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.

Time frame:
From enrollment to Day-7
Reported as:
Mean · No of amplification cycles for detection
Differenc in Change of N-Gene From Baseline to Day-7 Between NP-101 and Placebo
No of amplification cycles for detectionPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Differenc in Change of N-Gene From Baseline to Day-7 Between NP-101 and Placebo5.78 ± 7.269.79 ± 4.00
SecondaryRT-PCR Negative/Undetectable Rate at Day 7

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the percentage of RT-PCR negative/undetectable (i.e., viral clearance) on Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo

Time frame:
Days 0 to 7
Reported as:
Count of participants · Participants
RT-PCR Negative/Undetectable Rate at Day 7
ParticipantsPhase IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
RT-PCR Negative/Undetectable Rate at Day 73646
SecondaryRT-PCR Negative/Undetectable on Day-14

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the percentage of RT-PCR negative/undetectable (i.e., viral clearance) on Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo

Time frame:
Day 0 to Day-14
Reported as:
Count of participants · Participants
RT-PCR Negative/Undetectable on Day-14
ParticipantsPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
RT-PCR Negative/Undetectable on Day-144754
SecondaryMedian Time to Sustained Clinical Recovery

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of Sustained Clinical Recovery between NP-101 and Placebo arms

Time frame:
From Day-0 to Day-28
Reported as:
Median · Days from enrollment
Median Time to Sustained Clinical Recovery
Days from enrollmentPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Median Time to Sustained Clinical Recovery5 (4 to 5)4 (4 to 5)
SecondaryMedian Day to Complete Clinical Recovery

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of Sustained Clinical Recovery between NP-101 and Placebo arms

Time frame:
From Day-0 to Day-28
Reported as:
Median · Days from Enrollment
Median Day to Complete Clinical Recovery
Days from EnrollmentPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Median Day to Complete Clinical Recovery18 (7 to 23)20.5 (12 to 25)
SecondaryMedian Days to Complete Clinical Resolution

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of the complete clinical resolution between NP-101 and Placebo.

Time frame:
From Day-0 to Day-28
Reported as:
Median · Days from Enrollment
Median Days to Complete Clinical Resolution
Days from EnrollmentPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Median Days to Complete Clinical Resolution19 (11 to 27)23.5 (16 to 27)
SecondaryDifference of the Change From Randomization to Day-7 of Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+ Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. Markers are absolute counts of cells per cubic milimeter.

Time frame:
From Day-0 to Day-7
Reported as:
Mean · Counts of cells/mm^3
Difference of the Change From Randomization to Day-7 of Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
Counts of cells/mm^3Phase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
CD45+ CCR7 CD8⁺ (Absolute Count as cells/mm^3)648.10 ± 362.76553.27 ± 317.40
CD45⁺ CCR7⁺ CD8⁺ (Absolute Count as cells/mm^3)647.75 ± 411.72750.81 ± 505.66
CXCR3⁺ CD4⁺ (Absolute Count as cells/mm^3)125.86 ± 153.98130.01 ± 141.1
CCR7⁺ CXCR3⁺ CD8⁺ (Absolute Count as cells/mm^3)16.80 ± 26.6714.17 ± 15.66
CXCR3⁺ CD8⁺ (Absolute Count as cells/mm^3)1573.88 ± 609.671496.86 ± 518.6
CD8⁺ CD4⁺ (Absolute Count as cells/mm^3)21.96 ± 32.7719.05 ± 17.12
CCR7⁺ CXCR3⁺ CD4⁺ (Absolute Count as cells/mm^3)109.06 ± 130.88110.59 ± 124.01
CD45⁺ CD3⁺ CD8⁺ (Absolute Count as cells/mm^3)544.13 ± 235.08530.17 ± 240.16
CD45⁺ CD3⁺ CD4⁺ (Absolute Count as cells/mm^3)1051.97 ± 398.081018.03 ± 381.23
CD45_LYMPHOGATE (Absolute Count as cells/mm^3)2256.04 ± 738.122198.00 ± 655.61
CD45 CCR7⁺ CD8⁺ (Absolute Count as cells/mm^3)181.45 ± 146.63175.87 ± 179.88
CD45⁺ CCR7⁺ CD4⁺ (Absolute Count as cells/mm^3)942.70 ± 400.62954.23 ± 479.38
CD45 CCR7 CD4⁺ (Absolute Count as cells/mm^3)297.09 ± 238.68286.70 ± 202.4
CD45⁺ CCR7 CD8⁺ (Absolute Count as cells/mm^3)778.96 ± 457.08737.71 ± 401.83
CD45⁺ CD3⁺ CD16⁺ (Absolute Count as cells/mm^3)260.96 ± 142.8262.09 ± 135.68
CD45 CCR7⁺ CD4⁺ (Absolute Count as cells/mm^3)945.41 ± 464.32903.43 ± 411.39
CD45⁺ CD3⁺ CD19⁺ (Absolute Count as cells/mm^3)323.79 ± 143.12314.21 ± 134.1
CD45⁺ CD3⁺ (Absolute Count as cells/mm^3)1640.57 ± 577.191592.98 ± 512.35
CD45 CCR7 CD8⁺ (Absolute Count as cells/mm^3)34.64 ± 17.6833.94 ± 15.95
SecondaryDifference of the Change From Randomization to Day-7 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in the ratio of CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. Both CD4+ and CD8+ are measured as absolute counts of cells per cubic milimeter.

Time frame:
From Day-0 to Day-7
Reported as:
Mean · Ratio
Difference of the Change From Randomization to Day-7 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
RatioPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Difference of the Change From Randomization to Day-7 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.2.11 ± 0.832.17 ± 1.19
SecondaryDifference of the Change From Randomization to Day-7 of Percentages of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+ Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. These marker entries represent the percentages of the combination of these immune cell types or their percentages in the biological sample.

Time frame:
From Day-0 to Day-7 Cell Percentages
Reported as:
Mean · Percentage (%)
Difference of the Change From Randomization to Day-7 of Percentages of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
Percentage (%)Phase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
CXCR3⁺ CD8⁺ (%)0.58 ± 9.74-1.21 ± 8.31
CD45 CCR7 CD8⁺ (%)0.99 ± 8.62-0.29 ± 9.77
CXCR3⁺ CD4⁺ (%)-0.35 ± 9.95-0.27 ± 7.59
CCR7⁺ CXCR3⁺ CD8⁺ (%)-0.29 ± 6.830.04 ± 6.30
CD45 CCR7⁺ CD8⁺ (%)-0.50 ± 10.43-1.99 ± 7.50
CCR7⁺ CXCR3⁺ CD4⁺ (%)-0.06 ± 1.36-0.32 ± 1.81
CD8⁺ CD4⁺ (%)0.01 ± 0.88-0.08 ± 0.45
CD45⁺ CD16⁺ (%)-0.94 ± 4.67-1.43 ± 6.19
CD45⁺ CD3⁺ CD4⁺(%)0.04 ± 4.110.06 ± 3.76
CD45 CCR7⁺ CD4⁺ (%)-0.49 ± 9.270.34 ± 11.30
CD45⁺ CD3⁺ CD8⁺ (%)-0.05 ± 3.181.04 ± 6.47
CD45⁺ CCR7 CD8⁺ (%)0.02 ± 5.331.95 ± 3.59
CD45⁺ CD3⁺ (%)0.22 ± 4.82-0.52 ± 6.34
CD45⁺ CD3⁺ CD19⁺ (%)0.62 ± 2.671.83 ± 3.03
CD45⁺ CCR7⁺ CD4⁺ (%)-0.49 ± 9.270.34 ± 11.30
CD45 CCR7 CD4⁺ (%)0.26 ± 8.612.10 ± 8.24
SecondaryDifference of the Change From Randomization to Day-14 of Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+. Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. Markers are absolute count of cells per cubic milimeter.

Time frame:
From Day*0 to Day-14
Reported as:
Mean · cells/mm^3
Difference of the Change From Randomization to Day-14 of Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
cells/mm^3Phase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
CD45+ CCR7 CD8⁺ (Absolute Count as cells/mm^3)630.96 ± 348.84568.31 ± 329.50
CD45⁺ CCR7⁺ CD8⁺ (Absolute Count as cells/mm^3)627.99 ± 401.92678.60 ± 448.71
CCR7⁺ CXCR3⁺ CD8⁺ (Absolute Count as cells/mm^3)16.61 ± 29.7714.84 ± 18.14
CXCR3⁺ CD8⁺ (Absolute Count as cells/mm^3)1560.93 ± 521.791485.02 ± 506.68
CD8⁺ CD4⁺ (Absolute Count as cells/mm^3)18.82 ± 16.6720.10 ± 17.94
CCR7⁺ CXCR3⁺ CD4⁺ (Absolute Count as cells/mm^3)103.07 ± 123.04106.19 ± 89.02
CD45⁺ CD3⁺ CD8⁺ (Absolute Count as cells/mm^3)524.73 ± 215.27496.46 ± 219.66
CD45⁺ CD3⁺ CD4⁺ (Absolute Count as cells/mm^3)1018.27 ± 396.09963.24 ± 403.13
CD45_LYMPHOGATE (Absolute Count as cells/mm^3)2219.08 ± 687.912075.25 ± 665.69
CD45 CCR7⁺ CD8⁺ (Absolute Count as cells/mm^3)168.47 ± 125.91146.68 ± 107.73
CD45⁺ CCR7⁺ CD4⁺ (Absolute Count as cells/mm^3)924.25 ± 345.16912.86 ± 445.05
CD45 CCR7 CD4⁺ (Absolute Count as cells/mm^3)278.61 ± 168.56266.41 ± 181.75
CD45⁺ CCR7 CD8⁺ (Absolute Count as cells/mm^3)775.97 ± 401.74672.74 ± 362.52
CD45⁺ CD3⁺ CD16⁺ (Absolute Count as cells/mm^3)662.39 ± 2851.03252.65 ± 137.30
CD45 CCR7⁺ CD4⁺ (Absolute Count as cells/mm^3)937.05 ± 440.55841.36 ± 426.28
CD45⁺ CD3⁺ CD19⁺ (Absolute Count as cells/mm^3)325.93 ± 135.74288.91 ± 125.42
CD45⁺ CD3⁺ (Absolute Count as cells/mm^3)1587.71 ± 561.101501.06 ± 522.98
CD45 CCR7 CD8⁺ (Absolute Count as cells/mm^3)35.26 ± 16.3132.75 ± 15.22
SecondaryDifference of the Change From Randomization to Day-14 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in the ratio of CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. Both CD4+ and CD8+ are measured as absolute counts of cells per cubic milimeter.

Time frame:
From Day-0 to Day-14
Reported as:
Mean · Ratio
Difference of the Change From Randomization to Day-14 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
RatioPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Difference of the Change From Randomization to Day-14 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.2.10 ± 0.812.20 ± 1.11
SecondaryDifference of the Change From Randomization to Day-14 of Percentages of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+. Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. These Markers represent the percentages of the combination of these immune cell types or their percentages in the biological sample.

Time frame:
From Day-0 to Day-14
Reported as:
Mean · Percentage
Difference of the Change From Randomization to Day-14 of Percentages of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
PercentagePhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
CXCR3⁺ CD8⁺ (%)1.68 ± 9.122.40 ± 8.03
CD45⁺ CCR7⁺ CD8⁺ (%)-0.29 ± 9.76-2.31 ± 10.78
CD45 CCR7 CD8⁺ (%)0.77 ± 8.061.53 ± 6.91
CXCR3⁺ CD4⁺ (%)-0.38 ± 7.40-0.07 ± 7.12
CCR7⁺ CXCR3⁺ CD8⁺ (%)-0.43 ± 6.170.15 ± 5.69
CD45 CCR7⁺ CD8⁺ (%)-0.10 ± 10.67-3.18 ± 8.86
CCR7⁺ CXCR3⁺ CD4⁺ (%)0.05 ± 2.13-0.23 ± 1.86
CD8⁺ CD4⁺ (%)0.01 ± 0.520.00 ± 0.99
CD45⁺ CD16⁺ (%)-0.86 ± 4.81-1.34 ± 5.54
CD45⁺ CD3⁺ CD4⁺(%)-0.42 ± 4.75-0.08 ± 3.54
CD45 CCR7⁺ CD4⁺ (%)0.58 ± 7.871.31 ± 7.82
CD45⁺ CD3⁺ CD8⁺ (%)-0.35 ± 2.66-0.46 ± 4.77
CD45⁺ CCR7 CD8⁺ (%)-0.07 ± 4.861.71 ± 3.50
CD45⁺ CD3⁺ (%)-0.50 ± 4.84-0.60 ± 5.50
CD45⁺ CD3⁺ CD19⁺ (%)1.17 ± 2.831.57 ± 2.91
CD45⁺ CCR7⁺ CD4⁺ (%)-0.38 ± 6.340.78 ± 7.53
CD45 CCR7 CD4⁺ (%)0.58 ± 7.871.31 ± 7.82
SecondaryProportion of Participants With Symptom Progression

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the rate of disease progression measured by the worsening by the Covid-19 symptoms from 'none' or 'mild' to 'moderate' or 'severe' and remaining at that level for at least two days before alleviation or resolution, or the experience of hospitalization or death due to Covid-19 symptom worsening in participants taking the MED of NP-101 versus placebo

Time frame:
From Day-0 to Day28
Reported as:
Count of participants · Participants
Proportion of Participants With Symptom Progression
ParticipantsPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Proportion of Participants With Symptom Progression824
SecondaryProportion of Paticipants With Long-Covid Symptoms

This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the rate of Long- Covid symptoms in participants taking the MED of NP-101 versus placebo. A patient will be classified as having experienced symptoms indicative of Long- Covid if they reported any new or ongoing mild, moderate, or severe Long- Covid symptoms captured on the daily symptom questionnaire, on any of the following days: Day 30 ± 2 days, Day 37 ± 2 days, or Day 45 ± 2 days

Time frame:
Day-29 to Day-45
Reported as:
Count of participants · Participants
Proportion of Paticipants With Long-Covid Symptoms
ParticipantsPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
Proportion of Paticipants With Long-Covid Symptoms1224

Adverse events

Collected over From enrollment until the end of Day 45. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase-IIa NP-101 Dose 3g0/15 (0%)0/15 (0%)4/15 (26.7%)
Phase-IIa Placebo, Dose 3g0/5 (0%)0/5 (0%)3/5 (60%)
Phase-IIa NP-101, Dose 4.8g0/15 (0%)0/15 (0%)6/15 (40%)
Phase-IIa Placebo, Dose 4.8g0/5 (0%)0/5 (0%)3/5 (60%)
Phase-IIa NP-101, Dose 6g0/15 (0%)0/15 (0%)12/15 (80%)
Phase-IIa Placebo, Dose 6g0/5 (0%)0/5 (0%)4/5 (80%)
Phase-IIb NP-101, Dose 6g0/50 (0%)0/50 (0%)12/50 (24%)
Phase-IIb Placebo, Dose 6g0/60 (0%)0/60 (0%)21/60 (35%)
Most frequent other events
Showing 10 of 40
Most frequent other events
EventPhase-IIa NP-101 Dose 3gPhase-IIa Placebo, Dose 3gPhase-IIa NP-101, Dose 4.8gPhase-IIa Placebo, Dose 4.8gPhase-IIa NP-101, Dose 6gPhase-IIa Placebo, Dose 6gPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6g
DiarrheaGastrointestinal disorders1/152/53/150/52/153/58/5012/60
NauseaGastrointestinal disorders0/153/52/151/52/150/53/504/60
Abdominal PainGastrointestinal disorders0/152/51/150/50/150/51/500/60
HeadacheNervous system disorders1/150/51/150/51/151/53/505/60
Alt IncreasedHepatobiliary disorders0/150/50/150/50/151/50/500/60
Ast IncreasedHepatobiliary disorders0/150/50/150/50/151/50/500/60
Bicarbonate Decreased SerumMetabolism and nutrition disorders1/151/50/150/51/151/50/500/60
Blood Bicarbonate LowRenal and urinary disorders0/150/50/150/50/151/50/500/60
Chest painCardiac disorders0/151/50/150/50/151/50/500/60
DiaphoresisSkin and subcutaneous tissue disorders0/150/50/151/50/150/50/500/60

Baseline characteristics

The study enrolled a total of 170 participants, of whom 60 were enrolled during the dose-finding component (Phae-IIa)

Age, Continuous
Age, Continuous(Year)Phase-IIa NP-101, Dose 3gPhase-IIa Placebo, Dose 3gPhase-IIa NP-101, Dose 4.8gPhase-IIa Placebo, Dose 4.8gPhase-IIa NP-101, Dose 6gPhase-IIa Placebo, Dose 6gPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6gTotal
Mean41.53 ± 14.0341.05 ± 7.9547.54 ± 14.7245.51 ± 28.2242.53 ± 13.9347.58 ± 19.1346.04 ± 14.1443.84 ± 14.0744.59 ± 14.49
Sex: Female, Male
Sex: Female, Male(Participants)Phase-IIa NP-101, Dose 3gPhase-IIa Placebo, Dose 3gPhase-IIa NP-101, Dose 4.8gPhase-IIa Placebo, Dose 4.8gPhase-IIa NP-101, Dose 6gPhase-IIa Placebo, Dose 6gPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6gTotal
Female111831243938116
Male447231112254
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase-IIa NP-101, Dose 3gPhase-IIa Placebo, Dose 3gPhase-IIa NP-101, Dose 4.8gPhase-IIa Placebo, Dose 4.8gPhase-IIa NP-101, Dose 6gPhase-IIa Placebo, Dose 6gPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6gTotal
American Indian or Alaska Native000000022
Asian111011229
Native Hawaiian or Other Pacific Islander000000000
Black or African American3021214720
White837241353494
More than one race000000000
Unknown or Not Reported31528291545
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase-IIa NP-101, Dose 3gPhase-IIa Placebo, Dose 3gPhase-IIa NP-101, Dose 4.8gPhase-IIa Placebo, Dose 4.8gPhase-IIa NP-101, Dose 6gPhase-IIa Placebo, Dose 6gPhase-IIb NP-101, Dose 6gPhase-IIb Placebo, Dose 6gTotal
Hispanic or Latino103104824248127
Not Hispanic or Latino52517381243
Unknown or Not Reported000000000
08

Study locations

4 sites
  • L&A Morales Healthcare/ Enrique Villa, MD Principal Investigator
    Miami, Florida 33142, United States
  • Research Network America
    Berwyn, Illinois 60402, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • Pearland Family Wellness Clinic
    Pearland, Texas 77584, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in May 2025, 26 months.

Results were first posted in Aug 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2023
First posted
Mar 27, 2023
StartActual
Feb 22, 2023
Primary completionActual
May 9, 2025
CompletionActual
May 9, 2025
Results first posted
Aug 13, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05785390
Lead sponsor
Novatek Pharmaceuticals
Responsible party
Sponsor
First posted
Mar 27, 2023
Start date
Feb 22, 2023
Primary completion
May 9, 2025
Completion
May 9, 2025
Results posted
Aug 13, 2026
Last update
Aug 13, 2026

Study contacts

Ahmed Kaseb, MD
study director · Novatek Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nigella sativa oil · Black Seed Oil Extract Supplement

Start the discussion